Loading…

CorMedix Inc.CRMDCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 7
Mkt cap
$358M
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$12.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+39.5 pp
WACC 10.5%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · USD$4.50
1D-3.6%
1W-15.1%
1M-40.5%
3M-45.3%
6M-43.2%
YTD-61.3%
1Y-54.9%
ATR %8.9%
Beta1.27
52w lowhigh65.4% off high

What CorMedix does

Employees: 191

CorMedix at a glance

Size CorMedix (CRMD) is a United States Health Care company (Biotechnology) with a market value of $358M, the 2937th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.50 on 18 Nov 2026.

Performance Over six months the shares fell 43.2%, against -31.1% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 92.5% over the last twelve months (peer median +6.8%); the operating margin is 38.6% (peer median -9.8%).

Valuation It trades at 0.4× enterprise value to sales against a peer median of 5.2× (cheapest of 16).

Capital Return on invested capital runs 39.5 points above its cost of capital (10.5% WACC).

Short interest Short interest is 18.2% of the free float (30 Oct 2026).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 69CRMD 56
Six months, rebased to 100: CorMedix against the median of its 20 peers (local-currency closes).

CorMedix financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$412M$312M$43.5M$0$65,408
Revenue growth—+617%—-100%—
Gross profit$320M$276M$40.3M-$205,562-$147,364
EBITDA$201M$165M-$21.9M-$48.8M-$30.4M
Net income$63.9M$163M-$17.9M-$46.3M-$29.7M
Free cash flow$307M$173M-$50.7M-$38.7M-$24.6M
Capital expenditure$4.92M$2.26M$115,730$327,300$219,360
Total debt$145M$149M$517,013$667,632$802,433

Quarterly statements and history in the cockpit →

CorMedix competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-25%0%+25%CTNM086900476060300381LYEL358570PRTCLRMRALEC3009663880PNV6886872105CCCC7630CRMD6-month return →1-month return →
Up and to the right = strong over both horizons. CorMedix is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×086900476060300381LYEL3585707630CRMDRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CorMedix is the large dot.

CorMedix competitors and peer comparison

How CorMedix compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CorMedix against its 20 peers (data as of 18 Nov 2026)
MeasureCRMDPeer medianRank in peer set
1-month return-40.5%-2.0%lowest of 20
6-month return-43.2%-31.1%5th lowest of 20
Distance from 52-week high-65.4%-49.1%5th lowest of 20
Revenue growth (TTM)+92.5%+6.8%5th highest of 15
Operating margin38.6%-9.8%highest of 16
EV / Sales0.4×5.2×cheapest of 16
ROIC minus cost of capital+39.5 pp-9.4 pp2nd highest of 16
EV / EBITDA0.7×16.6×cheapest of 7
Net debt / EBITDA-1.1×-2.9×2nd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a

Questions

Which companies are CorMedix's closest peers?
The cockpit's peer set: Contineum Therapeutics (CTNM), Medy-Tox (086900.KS), Aspen Neuroscience (ASPE), Onconic Therapeutics (476060.KS), Guangdong Vtr Bio-Tech (300381.SZ), Lyell Immunopharma (LYEL), GI Innovation (358570.KS), PureTech Health (PRTC.L).
Is CorMedix expensive compared with its peers?
On ev / sales it trades at 0.4× against a peer median of 5.2×, cheapest of 16 in its peer set.
How has CorMedix stock performed?
Over six months to 18 Nov 2026 the shares returned -43.2% against -31.1% for the median peer; over one year -54.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.